Entrada Therapeutics, Inc. Common Stock

TRDANASDAQ • USD
5.09 USD
↘ 0.00 (0.10%)🟢PRE MARKET (AS OF 04:00 AM EST)
🟢Market: OPEN

TRDA is currently priced at $5.09. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. Notable factors include a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. Valuation metrics place TRDA at a fair price relative to peers.

Technical & fundamental data as of Nov 13, 2026.

Open?$5.09
High?$5.09
Low?$5.09
Prev. Close?$5.09
Volume?0
Avg. Volume?462.6K
Bid / Ask
Bid?$4.35 × 100
Ask?$5.82 × 100
Spread?$1.47
Midpoint?$5.09
Valuation & Ratios
Market Cap?199.3M
Shares Out?39.2M
Float?25.1M
Float %?64.5%
P/E Ratio?N/A
P/B Ratio?1.00
EPS?-$4.12
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
Employees
152
Market Cap
199.3M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2021-10-29
Address
ONE DESIGN CENTER PLACE
BOSTON, MA 02210
Phone: 857-305-1825
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-1/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
23
Short Sent.?
59
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.63Distress
Confidence?54%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?11.17%High
Short Interest?2.8M
Days to Cover?6.9
Free Float25.1M
Avg Daily Volume408.2K
Settlement Date2026-10-30
Financial Health
Current Ratio?7.85Strong
Quick Ratio?7.85Strong
Cash Ratio?4.34Strong
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
1.00CHEAP▾
P/S?
Peers
100
S&P
3
50.11HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-0.5CHEAP▾
EV/Sales?
Peers
100
S&P
3
21.89HIGH▾
Returns & Efficiency
ROE?
S&P
3
-81.4%WEAK▾
ROA?
S&P
3
-60.5%WEAK▾
Cash Flow & Enterprise
FCF?$-136334000
Enterprise Value?$87.0M
Fundamentals ratios updated end of day